Psychedelic Bulletin
Your weekly update on the psychedelics space. Connect the dots in this fast-paced ecosystem with exclusive insights, analysis, and expert comment.
Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of Oregon Opt-out; Sensorium Closes $30m Series A
This week: Colorado’s Prop 122 passes, decriminalising a number of psychedelics and establishing regulated psilocybin therapy; many Oregon counties opt-out; Sensorium closes $30m Series A round; and much more…
Psychedelic Bulletin #122: Lusaris Raises $60m to Develop 5-MeO-DMT; First Take-Home Psilocybin Trial in N. America; COMPASS Phase 2b Published in NEJM
This week: we take a look at the newest 5-MeO-DMT company to emerge; COMPASS’ Phase 2b psilocybin trial published in NEJM; Apex Labs set to trial take-home psilocybin; and much more…
Psychedelic Bulletin #121: The State of Psychedelic Economy and Industry; Dispatch from Horizons New York 2022
This week: Our preliminary dispatch from Horizons New York 2022; a write-up of a presentation on the state of psychedelic economy and industry; company news; and more…
Psychedelic Bulletin #120: Beckley Psytech Acquires Eleusis; A Look at COMPASS’ Phase 3 Design; New Psychedelic Drug Dev Scoops $22m Series A
This week: we take a look at COMPASS Pathways’ Phase 3 program; our quick take reaction to Beckley Psytech’s acquisition of Eleusis; Empyrean Neuroscience exits stealth with a $22m Series A; and much more…
Psychedelic Bulletin #119: More Misery for MindMed; Another Psychedelics Co. Ceases Operations; A Brief Dispatch from ICPR
This week: MindMed continues to face troubles amidst shareholder activist situation; Onsero Therapeutics looks to skip the trip; Havn ceases operations; a brief dispatch from ICPR; and more…
Psychedelic Bulletin #118 – San Francisco ‘Decriminalizes’ Psychedelics
This week: SF Decriminalizes Psychedelics, But What Does That Mean? and more…